The notices it replaced
- Reissues: PAR-24-223 Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
- 2 steps back: PAR-22-047 Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
- 3 steps back: PAR-18-820 Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
- 4 steps back: PAR-18-174 Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
- 5 steps back: PAR-15-174 Alzheimer's Drug-Development Program (U01)
- 6 steps back: PAR-12-015 Alzheimer's Disease Drug Development Program (U01)
- 7 steps back: PA-10-205 Alzheimers Disease Drug Development Program (U01)
- 8 steps back: PAR-08-266 Alzheimers Disease Drug Development Program (U01)
- 9 steps back: PAR-05-148
Who won it before
39 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $55,317,999 in first-year total cost, median $1,480,275.
Most frequent study sections
- Special Emphasis Panel[ZAG1 ZIJ-6 (J3)]10
- Special Emphasis Panel[ZAG1 ZIJ-6 (M3)]4
- Special Emphasis Panel[ZAG1 ZIJ-6 (M1)]3
- Special Emphasis Panel[ZAG1 ZIJ-6 (O2)]3
- Special Emphasis Panel[ZAG1 ZIJ-G (M1)]3
Most frequent institutions
- UNIVERSITY OF ARIZONA4
- UNIVERSITY OF CALIFORNIA, SAN DIEGO4
- INSTITUTE FOR MOLECULAR MEDICINE3
- BRIGHAM AND WOMEN'S HOSPITAL2
- EMORY UNIVERSITY2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Optimization of SHIP1 Inhibitors for the Treatment of Alzheimer's Disease1U01AG088021-01 · under PAR-22-047 | LAMB, BRUCE TMESECAR, ANDREW DOBLAK, ADRIAN LYNNPALKOWITZ, ALAN D.RICHARDSON, TIMOTHY I | INDIANA UNIVERSITY INDIANAPOLIS, IN | $2,217,438 | ZAG1 |
| 2025 | In vitro pharmacology, chronic toxicology, and embryo-fetal development studies to demonstrate safety of GSM-7796901U01AG094588-01 · under PAR-22-047 | GALASKO, DOUGLAS R | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $1,612,640 | ZAG1 |
| 2025 | Drug Development for Alzheimer's neuroinflammation1U01AG094622-01 · under PAR-22-047 | CHEN, KAIKATRITCH, VSEVOLODLOUIE, STAN GEEYASSINE, HUSSEIN N | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $1,480,275 | ZAG1 |
| 2024 | Development of a MT-stabilizing agent for the treatment of tauopathies1U01AG088051-01 · under PAR-22-047 | BRUNDEN, KURT R.CAFFREY, CONOR | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $2,309,108 | ZAG1 |
| 2024 | IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)1U01AG084528-01 · under PAR-22-047 | AGADJANYAN, MICHAEL GGALVIN, JAMES E | INSTITUTE FOR MOLECULAR MEDICINE, CA | $1,791,614 | ZAG1 |
| 2024 | Development of EP2 Receptor Antagonist to Treat Alzheimer's Disease1U01AG088113-01 · under PAR-22-047 | GANESH, THOTAHONORE, TAGE | EMORY UNIVERSITY, GA | $1,737,244 | ZAG1 |
| 2024 | Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD1U01AG084549-01 · under PAR-22-047 | MAHER, PAMELA ANNERASCHKE, WILLIAM C | VIROGENICS, INC., CA | $1,594,649 | ZAG1 |
| 2023 | Developing a NAMPT activator for Alzheimer’s disease1U01AG079828-01A1 · under PAR-22-047 | CHEN, BEIBEIRIZZO, STACEY J | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $2,380,457 | ZAG1 |
| 2023 | PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology Study1U01AG082617-01 · under PAR-22-047 | HAY, MEREDITHVANDERAH, TODD W | UNIVERSITY OF ARIZONA, AZ | $2,208,081 | ZAG1 |
| 2023 | Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial1U01AG082687-01 · under PAR-22-047 | KELLEHER-ANDERSSON, JUDITH A | NEURONASCENT, INC., MD | $2,100,000 | ZAG1 |
| 2022 | GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease1U01AG076480-01 · under PAR-18-820 | VAN ELDIK, LINDA JWATTERSON, DANIEL MARTIN | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $1,546,977 | ZAG1 |
| 2022 | Novel Reengineered Microbiome-based Biologic Therapy to Treat Cognitive and Behavioral Symptoms of Alzheimer's Disease and Related Dementias1U01AG074960-01A1 · under PAR-18-820 | KANTHASAMY, ANUMANTHA GOUNDERPHILLIPS, JAMES GREGORY | UNIVERSITY OF GEORGIA, GA | $1,459,176 | ZAG1 |
| 2022 | Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease1U01AG076481-01 · under PAR-18-820 | ZHANG, SHIJUN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $1,426,573 | ZAG1 |
| 2022 | Preclinical and early clinical development of a GABA-A a5 PAM1U01AG074950-01A1 · under PAR-18-820 | ROSENZWEIG-LIPSON, SHARON | AGENEBIO, INC., MD | $1,100,000 | ZAG1 |
| 2022 | Nonlipogenic ABCA1 inducers for ADRD1U01AG076450-01 · under PAR-18-820 | THATCHER, GREGORY R. J | UNIVERSITY OF ARIZONA, AZ | $756,926 | ZAG1 |
| 2021 | Discovery of Drugs that Modulate Neuroinflammation for the treatment of Alzheimer's Disease1U01AG066759-01A1 · under PAR-18-820 | HODGETTS, KEVIN | BRIGHAM AND WOMEN'S HOSPITAL, MA | $1,770,176 | ZAG1 |
| 2021 | A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease1U01AG073148-01 · under PAR-18-820 | YUEN, TONYZAIDI, MONE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $1,712,573 | ZAG1 |
| 2021 | Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders1U01AG068823-01A1 · under PAR-18-820 | REITZ, ALLEN BERNARD | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $1,412,771 | ZAG1 |
| 2021 | Safety and Tolerability Studies for an Anti-Fibrin P2 Monoclonal Antibody for the Treatment of Alzheimer's Disease1U01AG073125-01 · under PAR-18-820 | STAVENHAGEN, JEFFREY | THERINI BIO, INC., CA | $987,080 | ZAG1 |
| 2021 | Optimization and evaluation of novel benzimidazoles for the treatment of Alzheimer's Disease1U01AG071495-01 · under PAR-18-820 | HODGETTS, KEVIN | BRIGHAM AND WOMEN'S HOSPITAL, MA | $887,312 | ZAG1 |
| 2020 | Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease1U01AG068031-01 · under PAR-18-820 | WANG, JINZHENG, HUI | BAYLOR COLLEGE OF MEDICINE, TX | $1,809,984 | ZAG1 |
| 2020 | Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease1U01AG066757-01 · under PAR-18-820 | GOATE, ALISON MRAY, WILLIAM JTSAI, LI-HUEI | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $1,623,635 | ZAG1 |
| 2020 | Development of a small-molecule that enhances tripartite synapses for Alzheimers disease1U01AG068822-01 · under PAR-18-820 | LIN, CHIEN-LIANG GLENN | OHIO STATE UNIVERSITY, OH | $1,552,548 | ZAG1 |
| 2020 | IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.1U01AG063768-01A1 · under PAR-18-820 | RODGERS, KATHLEEN E. | UNIVERSITY OF ARIZONA, AZ | $1,533,089 | ZAG1 |
| 2020 | IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia1U01AG066623-01 · under PAR-18-820 | HAY, MEREDITHKONHILAS, JOHN PMANSOUR, HEIDI M. | UNIVERSITY OF ARIZONA, AZ | $1,506,750 | ZAG1 |
| 2020 | Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment1U01AG066722-01 · under PAR-18-820 | ARANCIO, OTTAVIOWATTERSON, DANIEL MARTIN | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $1,475,773 | ZAG1 |
| 2019 | IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial1U01AG060965-01 · under PAR-18-174 | AGADJANYAN, MICHAEL G | INSTITUTE FOR MOLECULAR MEDICINE, CA | $1,116,260 | ZAG1 |
| 2019 | Long-term toxicology studies for Posiphen; 6 month in rats and 9 months in dogs1U01AG056437-01A1 · under PAR-18-820 | MACCECCHINI, MARIA | ANNOVIS BIO, INC., PA | $953,849 | ZAG1 |
| 2019 | Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies1U01AG061173-01 · under PAR-18-174 | BALLATORE, CARLOBRUNDEN, KURT R. | UNIVERSITY OF PENNSYLVANIA, PA | $948,369 | ZAG1 |
| 2018 | Silent Allosteric Modulation of mGluR5 for Safe and Effective Therapy of Alzheimer's Disease1U01AG058608-01A1 · under PAR-15-174 | STRITTMATTER, STEPHEN M | YALE UNIVERSITY, CT | $1,646,216 | ZAG1 |
| 2018 | Neural Stem Cell Transplantation: A Novel Cellular Therapy for Alzheimer's Disease1U01AG057562-01A1 · under PAR-15-174 | FELDMAN, EVA LUCILLEMURPHY, GEOFFREY G | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $687,010 | ZAG1 |
| 2017 | Development of small molecule activators of glutamate transporter EAAT2 for treatment of Alzheimer's disease1U01AG054444-01A1 · under PAR-15-174 | LIN, CHIEN-LIANG GLENN | OHIO STATE UNIVERSITY, OH | $772,430 | ZAG1 |
| 2017 | Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease1U01AG053247-01A1 · under PAR-15-174 | GOURE, WILLIAM | ACUMEN PHARMACEUTICALS, INC., VA | $444,503 | ZAG1 |
| 2016 | Optimization and preclinical development of soluble gamma-secretase modulators for AD1U01AG048986-01A1 · under PAR-12-015 | WAGNER, STEVEN LEE | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $1,514,460 | ZAG1 |
| 2016 | Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology1U01AG052460-01A1 · under PAR-15-174 | GANESH, THOTA | EMORY UNIVERSITY, GA | $758,149 | ZAG1 |
| 2015 | Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD1U01AG050636-01 · under PAR-12-015 | VAN ELDIK, LINDA JWATTERSON, DANIEL MARTIN | UNIVERSITY OF KENTUCKY, KY | $1,416,252 | ZAG1 |
| 2015 | Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND1U01AG048310-01A1 · under PAR-12-015 | AGADJANYAN, MICHAEL G | INSTITUTE FOR MOLECULAR MEDICINE, CA | $1,152,198 | ZAG1 |
| 2014 | A Translational Program of BDNF Gene Delivery in Alzheimer's Disease1U01AG043416-01A1 · under PAR-12-015 | TUSZYNSKI, MARK H. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $1,194,177 | ZAG1 |
| 2014 | Allopregnanolone a Regenerative Therapy for Alzheimer's: FDA-Required Toxicolog1U01AG047222-01 · under PAR-12-015 | BRINTON, ROBERTA EILEEN | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $721,277 | ZAG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.